Bhatt et al. uncovered that in LKB1-deficient KRAS-driven NSCLC, autophagy upregulation promotes resistance to MEK inhibition by inhibiting ferroptosis, highlighting the potential of autophagy inhibition combined with MEK inhibition as a therapeutic avenue (Bhatt et al., 2023). This evidence concerns the gene KRAS and non-small cell lung carcinoma.